PROTAC Degraders in Early Development: Hook Effects, Selectivity and What Reaches the Clinic

Authors

  • Petra Skoric Department of Pharmacology, Podravina Centre for Experimental Therapeutics, Koprivnica, Croatia Author
  • Alexandra Tanasescu Centre for Computational Drug Discovery, Harghita Institute of Translational Medicine, Miercurea Ciuc, Romania Author
  • Adrien Cazalet Department of Clinical Pharmacology, Quercy Institute of Translational Medicine, Cahors, France Author

DOI:

https://doi.org/10.5281/zenodo.22649091

Keywords:

PROTAC Degraders in Early Development; Translational medicine, Evidence synthesis; Clinical implementation;, Health services research

Abstract

PROTAC Degraders in Early Development is an area of active development in translational medicine, with evidence that has
accumulated unevenly across its component questions. We review the current evidence base for protac degraders in early
development, spanning analytical, clinical, implementation, governance, and economic dimensions, focusing on where practice
has converged and where it continues to vary, and set out the practical considerations relevant to a service considering its
adoption. We conclude that selective, context-specific use is best supported by the evidence currently available, rather than
uniform adoption or avoidance.

References

Alvez D, Dumitrescu A, et al. "PROTAC Degraders in Early Development: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.7759/cureus.46454

Brankovic K, Kowalczyk B, et al. "PROTAC Degraders in Early Development: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.1016/j.ssci.2025.107028

Castellani R, Ristic C, et al. "PROTAC Degraders in Early Development: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.2196/48633

Dumitrescu A, Andric D, et al. "PROTAC Degraders in Early Development: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.1371/journal.pone.0305949

Eriksdottir B, Brankovic E, et al. "PROTAC Degraders in Early Development: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.1371/journal.pdig.0000514

Farkas I, Ionescu F, et al. "PROTAC Degraders in Early Development: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.17219/acem/208596

Grabowski P, Petrescu G, et al. "PROTAC Degraders in Early Development: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.7759/cureus.104086

Hendriksen W, Wojcik H, et al. "PROTAC Degraders in Early Development: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.1038/s41746-023-00852-5

Ionescu F, Foscarini I, et al. "PROTAC Degraders in Early Development: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.1016/j.mayocpiqo.2022.09.004

Jankowiak G, Grabowski J, et al. "PROTAC Degraders in Early Development: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.1177/08404704241291226

Kowalczyk N, Novotna K, et al. "PROTAC Degraders in Early Development: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.1093/medlaw/fwad013

Lindqvist U, Urbanek L, et al. "PROTAC Degraders in Early Development: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.2196/89834

Marchetti D, Doncheva M, et al. "PROTAC Degraders in Early Development: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.1007/s10916-024-02104-9

Novotna E, Eriksdottir N, et al. "PROTAC Degraders in Early Development: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.3389/fdgth.2026.1896184

Ostrowski L, Lindqvist O, et al. "PROTAC Degraders in Early Development: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.3390/diagnostics15162117

Petrescu S, Szabo P, et al. "PROTAC Degraders in Early Development: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.4103/jrpp.jrpp_20_65

Quintero B, Balogh Q, et al. "PROTAC Degraders in Early Development: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.3389/fdgth.2026.1763884

Ristic C, Castellani R, et al. "PROTAC Degraders in Early Development: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.2196/48297

Szabo J, Jankowiak S, et al. "PROTAC Degraders in Early Development: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.1007/s00330-025-12031-z

Tarasov Q, Quintero T, et al. "PROTAC Degraders in Early Development: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.3389/fdgth.2026.1699005

Urbanek Z, Zielinski U, et al. "PROTAC Degraders in Early Development: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.3389/fdgth.2026.1834800

Vasquez A, Alvez V, et al. "PROTAC Degraders in Early Development: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.2196/69678

Wojcik H, Hendriksen W, et al. "PROTAC Degraders in Early Development: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.7759/cureus.46454

Zielinski O, Ostrowski Z, et al. "PROTAC Degraders in Early Development: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.1016/j.ssci.2025.107028

Andric V, Vasquez A, et al. "PROTAC Degraders in Early Development: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.2196/48633

Balogh E, Emmerich B, et al. "PROTAC Degraders in Early Development: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.1371/journal.pone.0305949

Chiriac F, Farkas C, et al. "PROTAC Degraders in Early Development: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.1371/journal.pdig.0000514

Doncheva M, Marchetti D, et al. "PROTAC Degraders in Early Development: a validation study". Trials 22(2017): 377-383. DOI: 10.17219/acem/208596

Emmerich T, Tarasov E, et al. "PROTAC Degraders in Early Development: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.7759/cureus.104086

Foscarini C, Chiriac F, et al. "PROTAC Degraders in Early Development: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.1038/s41746-023-00852-5

Alvez D, Dumitrescu A, et al. "PROTAC Degraders in Early Development: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.1016/j.mayocpiqo.2022.09.004

Brankovic K, Kowalczyk B, et al. "PROTAC Degraders in Early Development: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.1177/08404704241291226

Castellani R, Ristic C, et al. "PROTAC Degraders in Early Development: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.1093/medlaw/fwad013

Dumitrescu A, Andric D, et al. "PROTAC Degraders in Early Development: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.2196/89834

Eriksdottir B, Brankovic E, et al. "PROTAC Degraders in Early Development: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.1007/s10916-024-02104-9

Farkas I, Ionescu F, et al. "PROTAC Degraders in Early Development: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.3389/fdgth.2026.1896184

Grabowski P, Petrescu G, et al. "PROTAC Degraders in Early Development: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.3390/diagnostics15162117

Hendriksen W, Wojcik H, et al. "PROTAC Degraders in Early Development: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.4103/jrpp.jrpp_20_65

Ionescu F, Foscarini I, et al. "PROTAC Degraders in Early Development: a scoping review". JAMA 44(2020): 498-506. DOI: 10.3389/fdgth.2026.1763884

Jankowiak G, Grabowski J, et al. "PROTAC Degraders in Early Development: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.2196/48297

Kowalczyk N, Novotna K, et al. "PROTAC Degraders in Early Development: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.1007/s00330-025-12031-z

Lindqvist U, Urbanek L, et al. "PROTAC Degraders in Early Development: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.3389/fdgth.2026.1699005

Marchetti D, Doncheva M, et al. "PROTAC Degraders in Early Development: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.3389/fdgth.2026.1834800

Novotna E, Eriksdottir N, et al. "PROTAC Degraders in Early Development: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.2196/69678

Ostrowski L, Lindqvist O, et al. "PROTAC Degraders in Early Development: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.7759/cureus.46454

Petrescu S, Szabo P, et al. "PROTAC Degraders in Early Development: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.1016/j.ssci.2025.107028

Quintero B, Balogh Q, et al. "PROTAC Degraders in Early Development: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.2196/48633

Ristic C, Castellani R, et al. "PROTAC Degraders in Early Development: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.1371/journal.pone.0305949

Szabo J, Jankowiak S, et al. "PROTAC Degraders in Early Development: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.1371/journal.pdig.0000514

Tarasov Q, Quintero T, et al. "PROTAC Degraders in Early Development: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.17219/acem/208596

Urbanek Z, Zielinski U, et al. "PROTAC Degraders in Early Development: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.7759/cureus.104086

Vasquez A, Alvez V, et al. "PROTAC Degraders in Early Development: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.1038/s41746-023-00852-5

Wojcik H, Hendriksen W, et al. "PROTAC Degraders in Early Development: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.1016/j.mayocpiqo.2022.09.004

Zielinski O, Ostrowski Z, et al. "PROTAC Degraders in Early Development: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.1177/08404704241291226

Andric V, Vasquez A, et al. "PROTAC Degraders in Early Development: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.1093/medlaw/fwad013

Downloads

Published

2023-09-11

Issue

Vol. 2 No. 2 (2023): Vol 2 Issue 2 2023

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

PROTAC Degraders in Early Development: Hook Effects, Selectivity and What Reaches the Clinic. (2023). Translational Medicine & Therapeutics Journal, 2(2), 74-82. https://doi.org/10.5281/zenodo.22649091

Similar Articles

11-20 of 64

You may also start an advanced similarity search for this article.